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Purpose: To investigate a possible effect of chloroquine on urinary excretion of cloxacillin 
when chloroquine is administered concurrently with ampicillin-cloxacillin combination.  
Methods: Eight healthy adult volunteers received single oral doses of Ampiclox® (ampicillin-
cloxacillin combination) alone and in combination with chloroquine in a cross-over study 
design with one week washout period between the drug administrations. Total urine voided 
was collected from each volunteer at predetermined time intervals for a period of 9 hr. The 
urine was analyzed for cloxacillin by a reversed-phase HPLC method.  
Results: A significant reduction in the amount of cloxacillin excreted in urine was observed 
following the co-administration of chloroquine and the ampicillin-cloxacillin combination 
products. The mean total amount of cloxacillin (Du∞), maximum peak of excretion (Dumax) and 
% dose excreted after Ampliclox® was administered alone were 84.6 ± 57.0 mg, 49.5  ±41.6 
mg and 33.9 ± 22.7% respectively. The corresponding values after co-administration with 
chloroquine were 30.2 ± 27.2 mg, 13.5 ± 10.4 mg and 12.1 ±10.9%.  The respective times of 
maximum absorption (Tmax) and elimination half-life (t1/2) of cloxacillin were 2.7 ± 0.4 hr and 
0.7 ± 0.4 hr after Ampiclox® alone and 1.5 ± 0.8 hr and 0.6 ± 0.5 hr after co-administration of 
the two drugs. The results showed a significant decrease (p < 0.0001) in the mean total 
amount as well as % dose of cloxacillin excreted in urine by 64% and a significant reduction 
(p < 0.05) in the Tmax of excretion by 45%.  
Conclusion: There is appreciable reduction in the urinary excretion of cloxacillin when given 
concurrently with chloroquine. The mode of this interaction and possible therapeutic 
implication is unknown. However, caution should be exercised when prescribing or 
administering these two drugs together. 
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Introduction 
 
It is common for patients with multiple 
medical problems to be taking many drugs 
concomitantly1. It is also becoming 
increasingly obvious to physicians and other 
members of the health-care team that many 
drug combinations when used inappropria-
tely have the inherent potential to interact 
adversely2. The co-administration of 
antibiotics and antimalarial agents is 
common in the tropics as a result of frequent 
association of malaria with other infections 
such as respiratory tract infections, urinary 
tract infections and diarrhoea3.  
 
Earlier studies4, 5 revealed that the 
bioavailability of ampicillin and cloxacillin (β-
lactam antibiotics) is significantly reduced 
following oral co-administration with either 
chloroquine or proguanil both of which are 
antimalarial drugs. Chloroquine is widely 
used for the treatment and prophylaxis of 
falciparum malaria as well as for rheumatoid 
arthritis5. The combination of ampicillin and 
cloxacillin produces a broad spectrum 
antibiotic activity against both Gram positive 
and Gram negative bacteria. Specifically, 
cloxacillin is a penicillinase-resistant and 
acid-stable penicillin used for the treatment 
of infections caused by penicillinase 
producing Staphylococci and Pneumococci. 
In combination with ampicillin, it is available 
as Ampiclox® (SmithKline Beecham, Lagos, 
Nigeria) and other generic forms6.  
 
In 1985, Ali4 investigated the interaction 
between chloroquine and ampicillin in 
ampicillin-cloxacillin administered orally. Ali’s 
study did not evaluate the effect of 
chloroquine on cloxacillin bioavailability and 
there is currently no information on possible 
interaction of chloroquine with cloxacillin in 
ampicillin-cloxacillin combination. In this 
study, therefore, the effect of chloroquine on 
the urinary excretion of cloxacillin when 
chloroquine is administered concurrently with 




Materials and Methods 
 
Twelve healthy volunteers were recruited for 
this study but only eight of the volunteers 
complied fully with the protocol for the study 
and were included in the data presented. 
The eight volunteers included 6 males and 2 
females aged between 21 and 30 years 
(mean, 25.3 ± 3.2 years), and weighing 
between 51 and 69 kg (mean, 61 ± 5.7 kg). 
The continuation of the study with the eight 
volunteers is supported by recent kinetic 
studies that have reported limited number of 
subjects6, 7, 8. Consent was obtained from 
each volunteer after full explanation of the 
protocol. The study protocol was approved 
by the Joint Ethics Committee of University 
of Ibadan/University College Hospital 
(UI/UCH) Ibadan, Nigeria.  
 
The study was a simple cross-over design in 
which the volunteers were not on regular 
medication, abstained from drugs two weeks 
prior to the administration of the study drugs, 
and throughout the duration of the study. 
The volunteers observed an overnight fast 
and were in fasting state till four hr after 
receiving the drugs, after which food was 
given to them. 
 
On the day of the study, each subject 
received a single oral dose of 500 mg of 
Ampiclox® capsules (SmithKline Beecham, 
Lagos, Nigeria, Batch No. 007) comprising of 
250 mg cloxacillin and 250 mg ampicillin with 
a glass of water (250 ml). The subjects were 
allowed to take water ad libium after drug 
administration. Total urine voided was 
collected prior to and at 0-1, 1-2, 2-3, 3-5, 5-
7 and 7-9 hr after drug administration. The 
volume of urine voided at each time interval 
was measured and recorded. An aliquot (30 
ml) was stored in sample bottles.  
 
After a washout period of one week, 500 mg 
Ampiclox® and 600 mg chloroquine 
phosphate capsules (Capquin® from Evans 
Medical PLC, Lagos, Nigeria; Batch No. 009) 
were given concurrently with a glass of water 
(250 ml). Total urine voided was collected as 
stated above. The pH of all samples were 
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taken and then stored at –20 oC until 
analysis. Both the Ampiclox® and 
chloroquine capsules used in the study were 
subjected to pharmaceutical assessment 
including identification test, weight 
uniformity, and chemical assay following 
British Pharmacopoeia (BP) standards9, and 
were confirmed to meet the BP standards 
before they were used for this study.  
 
The urine samples were analysed for 
cloxacillin by a reversed-phase HPLC 
method using a modified method described 
by Treare et al.10 and Abuirje et al.11. An 
internal standard, dicloxacillin was used in 
the determination of the amount of cloxacillin 
in the various urine samples. Briefly stated, 
200 µl of the urine was diluted to 1 ml with 
distilled water. The diluted urine sample (0.5 
ml) was mixed with 0.1 ml of 10 µg/ml 
solution of the internal standard and made 
up to 1 ml with mobile phase consisting of 
methanol and 0.04 M sodium phosphate 
buffer, pH 4.5 (4.1:5.9). This was mixed in a 
vortex mixer for 20 sec., centrifuged at 3000 
rpm for 3 min and 20 µl of the supernatant 
injected onto the HPLC column (RP-8, 10cm 
x 4 mm) at a flow rate of 0.7 ml/min. 
Detection of cloxacillin was achieved with a 
UV detector at a wavelength of 225 nm.  
 
The between-day and within-day coefficient 
of variation (CV%) were assessed and found 
to vary between 2 and 10 % while the 
recovery was determined to be 99%. 
 
From the data obtained, the amount of 
unchanged drug (cloxacillin) excreted was 
determined for each subject. Pharmaco-
kinetic parameters (maximum peak of 
excretion [Dumax], time of maximum peak 
excretion [Tmax], total amount excreted 
unchanged [Du∞], % dose excreted and 
elimination half-life [t1/2]) were evaluated 
according to standard methods12. Results 
were recorded as mean ± SD. Statistical 
comparison of data was achieved using the 
paired Student’s T-test and F-test. At 95% 
confidence interval, any 2-tailed p-value less 




The chloroquine and Ampiclox® administered 
were well tolerated by the volunteers. 
However, one of the volunteers experienced 
reversible dizziness, visual disturbance and 
itching when chloroquine was administered 
while another volunteer experienced itching 
and rashes after intake of Ampiclox® alone 
and later withdrew from the study. The data 
for these latter volunteers were excluded 
from the data of the eight volunteers 
presented. 
 
Details of the pharmacokinetic parameters 
obtained from urine are shown in the Table. 
There were wide inter- and intra-individual 
variations in the excretion results obtained. 
The co-administration of chloroquine and 
Ampiclox® produced significant decrease (p 
< 0.0001) in Du∞, Dumax, % excreted and 
Tmax. of cloxacillin. Total amount of cloxacillin 
excreted decreased in seven of the eight 
subjects and this included a subject who had 
no cloxacillin in the urine. Up to 64% 
decrease in the mean cloxacillin content in 
urine was produced by the chloroquine (p < 
0.0001). The Tmax was significantly reduced 
by 45 % (p < 0.05). However, the t1/2 of 
cloxacillin was not significantly (p > 0.05) 
affected by the concurrent administration of 




Cloxacillin is rapidly but incompletely (30% – 
80%) absorbed from the gastrointestinal 
tract13, 14. It is bound to plasma protein to a 
great extent (about 94%), metabolized to 
limited extent and excreted unchanged in 
urine by glomerular filtration and renal 
tubular secretion13, 14.  The present study 
shows that chloroquine tremendously 
reduces the excretion of cloxacillin in urine in 
Ampiclox®. The excretion of cloxacillin when 
Ampiclox® was taken alone was determined 
to be approximately 3 times the amount 
when Ampiclox® was taken together with 
chloroquine. The mean percentage of 
cloxacillin excreted in urine (34%) when 
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Ampiclox® was administered alone was 
similar to that of earlier reports13. In the 
presence of chloroquine, the reduction in 
urinary excretion of cloxacillin (mean, 64.4%) 
suggests significant interaction between 
chloroquine and cloxacillin. The wide inter- 
and intra-individual variations in the urinary 
data presented can be explained on the 
basis of erratic nature of drug excretion in 
urine, which is also related to pH changes15. 
Although urine sampling is one of the non-
invasive methods of drug level monitoring 
and can be convenient for pharmacokinetic 
studies especially for drugs that are excreted 
in urine in appreciable quantities such as 
cloxacillin 15,16, it may be difficult to conclude 
that chloroquine reduces the bioavailability of 
cloxacillin in ampicillin-cloxacillin combina-
tion unless plasma level data are available 
for comparison. Chloroquine may have led to 
a reduction in plasma levels of the cloxacillin 
in the presence of chloroquine by enhancing 
the degradation of cloxacillin or reducing the 
absorption. Further studies are needed to 
confirm such possibilities. Whether there is 
increase or decrease in plasma concen-
tration of cloxacillin as a result of concurrent 
administration with chloroquine, the 
therapeutic implication is evident. 
 
Ali4 has earlier reported about 35 % 
reduction in urinary excretion of ampicillin by 
chloroquine when taken concurrently in 
seven volunteers, but the Tmax of excretion 
remained unchanged. In a similar study 
carried out in our laboratory5, proguanil 
reduced the urinary excretion of cloxacillin by 
about 50 % but the Tmax and t1/2 were not 
significantly affected. The effect of 
chloroquine on both the rate and extent of 
excretion of cloxacillin observed in the 
present study is more pronounced than the 
Table: Urinary excretion data of cloxacillin after administration of ampicillin-cloxacillin combination alone 
and with chloroquine to volunteers 
 























28.94 23.85 13.06 18.91 11.57 2.3 1.8 0.27 0.89 
2 156.23 
 
18.47 114.84 10.41 62.49 7.39 1.4 1.8 0.22 0.25 
3 135.52 
 
67.37 58.99 25.11 54.21 26.95 2.6 0.5 0.58 0.89 
4 154.23 
 
27.13 109.04 15.28 61.69 10.85 4.5 2.5 0.36 0.46 
5 87.85 
 
74.56 40.02 30.12 35.14 29.82 2.8 2.2 0.49 0.37 
6 47.19 
 
4.70 24.69 1.44 18.88 1.88 3.3 1.4 1.02 1.49 
7 20.20 
 
20.23 6.89 12.18 8.34 8.09 2.3 1.5 1.40 0.5 
8 28.15 
 
0.0 17.31 0 11.26 0.0 2.0 0 0.93 0 
Mean 
 
84.58  30.17 49.46 13.45 33.87 12.07 2.65 1.46 0.65 0.61 
sd 56.96 27.15 41.61 10.37 22.74 10.86 0.42 0.84 0.42 0.47 
 
 
Clox, cloxacillin; Cq, chloroquine; sd, standard deviation; ap < 0.0001; bp < 0.001; cp < 0.001; dp < 0.05; ep > 
0.05 
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earlier studies. Unfortunately, the mecha-
nism of this interaction is still unknown. 
Though without proof, Ali4 attributed the 
chloroquine interaction with ampicillin to 
possible slowing of gastric motility and 
enhancement of gut motility. It may also be 
possible that these antimalarials being basic 
could be forming complexes with these beta-
lactam penicillins thereby reducing 
absorption. Chloroquine is reported to exhibit 
antispasmolytic properties similar to 
papaverine, thus leading to inhibition of 
gastric motility17, 18. Such reduction in gastric 
motility may lead to acid hydrolysis of these 
penicillins. Further studies will be conducted 
to confirm whether there is reduction in the 
bioavailability of cloxacillin by the 
chloroquine, and to determine the 





The concurrent administration of chloroquine 
and ampicillin-cloxacillin combination leads 
to an interaction between the chloroquine 
and cloxacillin. This interaction results in 
significant reduction of urinary excretion of 
cloxacillin. Whether this interaction results in 
the reduction of the bioavailability of 
cloxacillin is as yet to clear. However, there 
is therapeutic implication. Thus, caution 
should be exercised when prescribing or 
administering chloroquine and cloxacillin for 
concurrent administration. If they must be 
administered to a patient, it may be essential 
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